The safety of tiotropium--the FDA's conclusions

N Engl J Med. 2010 Sep 16;363(12):1097-9. doi: 10.1056/NEJMp1008502. Epub 2010 Sep 8.

Authors

Theresa M Michele¹, Simone Pinheiro, Solomon Iyasu

Affiliation

¹ Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 20843240
DOI: 10.1056/NEJMp1008502

No abstract available

MeSH terms

Bronchodilator Agents / adverse effects*
Bronchodilator Agents / therapeutic use
Cardiovascular Diseases / chemically induced*
Cardiovascular Diseases / mortality
Clinical Trials as Topic
Drug Approval*
Humans
Meta-Analysis as Topic
Pulmonary Disease, Chronic Obstructive / drug therapy*
Scopolamine Derivatives / adverse effects*
Scopolamine Derivatives / therapeutic use
Tiotropium Bromide
United States
United States Food and Drug Administration*

Substances

Bronchodilator Agents
Scopolamine Derivatives
Tiotropium Bromide